Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
mRESVIA (mRNA-1345) is a messenger RNA-based vaccine developed to protect adults aged 60 years and older against respiratory syncytial virus (RSV), a common and potentially serious respiratory infection. As part of the innovative mRNA vaccine platform, mRESVIA encodes stabilized prefusion F glycoproteins of RSV subtypes A and B, triggering a robust immune response to prevent RSV-related lower respiratory tract disease. Individuals looking to buy mRESVIA can rely on its clinically demonstrated efficacy and safety, positioning the mRESVIA vaccine as a significant advancement in adult respiratory health.
| Fact Table | |
|---|---|
| Formula | Not applicable (mRNA-based biologic) |
| License | FDA approved (May 2024) |
| Bioavailability | Not applicable (intramuscular injection) |
| Legal status | Prescription Only |
| Chemical Name | mRNA-1345 (encoding RSV F protein) |
| Elimination half-life | mRNA degrades rapidly in vivo (estimated hours) |
| Dosage (Strength) | 0.5 mL containing 100 µg mRNA |
| Pregnancy | Consult Doctor (not widely studied in pregnancy) |
| Brands | mRESVIA |
| Protein binding | Not applicable |
| PubChem CID | Not listed (biologic) |
| MedlinePlus | Not yet assigned |
| ChEBI | Not applicable |
| ATC code | J07BX08 |
| DrugBank | DB17999 |
| KEGG | D12514 |
| Routes of administration | Intramuscular injection |
mRESVIA is administered as a single intramuscular injection, typically into the deltoid muscle. It should be given by a qualified healthcare professional in accordance with national immunization guidelines. Patients are advised to remain under observation for at least 15 minutes after administration to monitor for any immediate adverse reactions. The timing and eligibility for vaccination should be determined by a medical provider based on individual health status and local RSV prevalence.
The active component of mRESVIA is mRNA-1345, which consists of a lipid nanoparticle-encapsulated messenger RNA sequence encoding the stabilized prefusion F glycoproteins from RSV A and RSV B. Inactive ingredients include lipids (SM-102, cholesterol, DSPC, and PEG2000-DMG), buffer components (tromethamine, tromethamine hydrochloride), acetic acid, sodium acetate, and sucrose.
Before administering mRESVIA, healthcare providers should evaluate patients for a history of hypersensitivity reactions, immunocompromising conditions, or concurrent illnesses that may affect vaccine response. While the mRESVIA vaccine is well tolerated in clinical trials, ongoing pharmacovigilance is essential. Patients should be informed about the mRESVIA cost and availability in their region, as pricing may vary depending on insurance coverage and distribution channels. Providers should report any adverse events following immunization to the appropriate regulatory authority.
mRESVIA is contraindicated in individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. It should not be administered to those experiencing moderate or severe acute illness at the time of vaccination, including individuals with febrile conditions, unless directed otherwise by a healthcare provider.
Commonly reported side effects following administration of mRESVIA include:
Most side effects are mild to moderate and resolve within a few days. Severe allergic reactions are rare but require immediate medical attention.
What is mRESVIA (mRNA-1345)?
mRESVIA is an mRNA vaccine developed to protect adults against respiratory syncytial virus (RSV).
Who should receive mRESVIA?
It is recommended for adults aged 60 years and older to help prevent RSV-related illness.
How does mRESVIA work?
It uses messenger RNA (mRNA) to instruct cells to produce a protein from the RSV virus, prompting an immune response.
Is mRESVIA a live virus vaccine?
No, mRESVIA does not contain live virus. It cannot cause RSV infection.
How is mRESVIA given?
It is administered as a single injection, usually in the upper arm.
What are common side effects of mRESVIA?
Side effects may include pain at the injection site, fatigue, headache, muscle aches, and fever.
How soon does mRESVIA start working?
The immune response typically begins within a couple of weeks after vaccination.
Can I get mRESVIA if I have a cold or mild illness?
Yes, mild illness usually doesn’t prevent vaccination, but consult your healthcare provider.
Can mRESVIA be given with other vaccines?
In some cases, yes. Your provider will determine the best schedule based on your health status.
Do I need a booster dose of mRESVIA?
Current guidance recommends one dose. Booster recommendations may change as more data becomes available.
